Published in Cancer Weekly, October 1st, 2002
The growth of multiple myeloma, a bone marrow cancer that mostly affects men, depends on angiogenesis and oncogenic activity. 2-Methoxyestradiol (2ME2) regulates cancer growth influences such as apoptosis and angiogenesis.
Researchers at the Dana-Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts think 2ME2 may extend survival in multiple myeloma (MM) patients by enabling cancer cells to overcome resistance to standard therapies.
The Harvard team evaluated the effects of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.